Oral Fabry Drug Clears CHMP, Amicus Sets Up 'Searchable Mutation' Website
This article was originally published in Scrip
Executive Summary
Amicus Therapeutics Inc., which is having a roller coaster ride with its oral Fabry disease treatment, is now in touching distance of getting the drug approved in Europe. The EMA's advisory committee, CHMP, gave migalastat (Galafold) a positive recommendation on April 1, 2016 for the treatment of Fabry disease in all patients who have amenable genetic mutations.
You may also be interested in...
FDA Reversal Gives Amicus Renewed Hope For US Oral Fabry Launch
Amicus plans to file migalastat for Fabry disease in the US in the fourth quarter, after FDA gave the greenlight, reversing a decision last year to require an additional Phase III study.
FDA Reversal Gives Amicus Renewed Hope For US Oral Fabry Launch
Amicus plans to file migalastat for Fabry disease in the US in the fourth quarter, after FDA gave the greenlight, reversing a decision last year to require an additional Phase III study. Additional information includes European submission data and post-launch RWE.
Amicus Eyes Broad Future Label For Migalastat After Huge Filing Setback
US FDA recommends company start a new study of oral Fabry disease drug, to be designed using the agency's irritable bowel syndrome guidance for measuring efficacy in diarrhea.